<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>3160</number>
    <updateDate>2025-10-08T00:26:07Z</updateDate>
    <updateDateIncludingText>2025-10-08T00:26:07Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2023-05-09</introducedDate>
    <congress>118</congress>
    <legislationUrl>https://www.congress.gov/bill/118th-congress/house-bill/3160</legislationUrl>
    <cdata>
      <constitutionalAuthorityStatementText>&lt;pre&gt;[Congressional Record Volume 169, Number 78 (Tuesday, May 9, 2023)][House]From the Congressional Record Online through the Government Publishing Office [&lt;a href="https://www.gpo.gov"&gt;www.gpo.gov&lt;/a&gt;]By Mr. RASKIN:H.R. 3160.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, clause 3.The single subject of this legislation is:Transparency of pharmaceutical research costs.[Page H2173]&lt;/pre&gt;</constitutionalAuthorityStatementText>
    </cdata>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2023-05-12T15:45:56Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2023-05-09T16:00:35Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hsba00</systemCode>
        <name>Financial Services Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred To</name>
            <date>2023-05-09T16:00:40Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Pharmaceutical Research Transparency Act of 2023</title>
        <congress>118</congress>
        <number>1476</number>
        <type>S</type>
        <latestAction>
          <actionDate>2023-05-09</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2023-05-12</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2023-05-09</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsba00</systemCode>
            <name>Financial Services Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-05-09</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2023-05-09</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2023-05-09</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>R000606</bioguideId>
        <fullName>Rep. Raskin, Jamie [D-MD-8]</fullName>
        <firstName>Jamie</firstName>
        <lastName>Raskin</lastName>
        <party>D</party>
        <state>MD</state>
        <district>8</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>S001208</bioguideId>
        <fullName>Rep. Slotkin, Elissa [D-MI-7]</fullName>
        <firstName>Elissa</firstName>
        <lastName>Slotkin</lastName>
        <party>D</party>
        <state>MI</state>
        <district>7</district>
        <sponsorshipDate>2023-06-12</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
        <item>
          <name>Government information and archives</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
        <item>
          <name>Manufacturing</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
        <item>
          <name>Medical research</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
        <item>
          <name>Prescription drugs</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
        <item>
          <name>Research and development</name>
          <updateDate>2023-07-14T12:30:57Z</updateDate>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
        <updateDate>2023-05-18T17:00:28Z</updateDate>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2023-05-09</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2023-06-05T15:41:17Z</updateDate>
        <cdata>
          <text>&lt;p&gt;&lt;strong&gt;Pharmaceutical Research Transparency Act of 2023&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.&lt;/p&gt; &lt;p&gt;Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.&lt;/p&gt; &lt;p&gt;The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.&lt;/p&gt;</text>
        </cdata>
      </summary>
    </summaries>
    <title>Pharmaceutical Research Transparency Act of 2023</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <titleTypeCode>45</titleTypeCode>
        <title>Pharmaceutical Research Transparency Act of 2023</title>
        <updateDate>2024-07-24T15:22:20Z</updateDate>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <titleTypeCode>101</titleTypeCode>
        <title>Pharmaceutical Research Transparency Act of 2023</title>
        <updateDate>2024-05-24T13:40:17Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <titleTypeCode>6</titleTypeCode>
        <title>To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.</title>
        <updateDate>2024-03-18T20:44:57Z</updateDate>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2023-05-09T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-118hr3160ih/xml/BILLS-118hr3160ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2023-05-12</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
